恩扎卢胺联合醋酸阿比特龙治疗骨转移去势抵抗性前列腺癌患者
这项开放标签、单中心干预研究纳入60例进展性骨转移去势抵抗性前列腺癌(bmCRPC)患者,给予恩扎卢胺160mg与醋酸阿比特龙1000mg每日一次、泼尼松5mg每日两次。联合治疗安全性可控、未见有意义的药物相互作用,但疗效结果不支持该联合方案对未经选择的bmCRPC患者有显著获益。
要点
- 最常见不良事件为疲乏72%、高血糖67%、碱性磷酸酶升高53%、潮热43%。
- PSA下降≥50%者46例(77%),≥90%者29例(48%),中位无进展生存期251天。
- 恩扎卢胺稳态时醋酸阿比特龙Cmin较单用时降低约23%。
核心结论
- 恩扎卢胺联合醋酸阿比特龙安全性可控,未见有意义的药物相互作用;两药均有药效学活性且无反馈;疗效结果不支持该联合方案对未经选择的bmCRPC患者有显著获益。
研究设计与样本
- 开放标签、单中心干预研究,纳入60例进展性骨转移去势抵抗性前列腺癌(bmCRPC)患者。
- 干预为恩扎卢胺160mg与醋酸阿比特龙1000mg每日一次,泼尼松5mg每日两次。
- 评估不良事件、PSA反应、无进展生存期、肿瘤生物标志物/代谢物表达及Cmin血浆浓度。
主要发现
- 不限级别与因果性的常见不良事件包括疲乏(72%)、高血糖(67%)、碱性磷酸酶升高(53%)、潮热(43%)。
- 3级不良事件包括高血压(17%)、丙氨酸氨基转移酶升高(12%)、碱性磷酸酶升高(5%)、关节痛(5%);未报告治疗相关4级不良事件或死亡。
- 中位治疗终止时间为312天(95%CI 196.0-483.0),中位无进展生存期为251天(95%CI 147-337)。
- 第9周时肿瘤微环境雄激素、前体及核AR表达下降(p<0.001);基线肿瘤AR C/N端比值≥80%与治疗获益相关。
- 恩扎卢胺稳态时醋酸阿比特龙Cmin较单用时降低约23%(范围14.05-200.5ng/ml)。
关键数值与推荐
- PSA最大下降≥50%者46例(77%),≥90%者29例(48%)。
- 基线肿瘤AR C/N端比值≥80%与治疗获益相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文标题与摘要未单列局限性段落;研究为开放标签、单中心干预研究,共纳入60例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is hypothesised that cotargeting the androgen receptor (AR) and paracrine androgen biosynthesis with enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) will dissipate adaptive feedback loops observed with either agent alone. OBJECTIVE: To assess the safety, efficacy, androgen signalling/metabolome, and drug-drug interactions (DDIs) of enzalutamide with abiraterone acetate in progressive bone mCRPC (bmCRPC). DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-centre interventional study was conducted in bmCRPC patients. INTERVENTION: Enzalutamide 160mg and abiraterone acetate 1000mg once daily; prednisone 5mg twice daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adverse events (AEs), prostate-specific antigen (PSA) response, progression-free survival (PFS), tumour biomarker/metabolite expression, and Cmin plasma concentrations were evaluated. RESULTS AND LIMITATIONS: Sixty patients were enrolled. Common AEs independent of grade/causality included fatigue (72%), hyperglycaemia (67%), alkaline phosphatase (ALP) elevation (53%), and hot flush (43%). Grade 3 AEs included hypertension (17%), alanine aminotransferase elevation (12%), ALP elevation (5%), and arthralgia (5%). No treatment-related grade 4 AEs or deaths were reported. Median treatment-discontinuation time was 312d (95% confidence interval [CI] 196.0-483.0). Maximal PSA decline ≥50% and ≥90% occurred in 46 (77%) and 29 (48%) patients, respectively. Median PFS was 251d (95% CI 147-337). At week 9, median tumour microenvironment androgens, precursors, and nuclear AR expression decreased (p<0.001). The baseline tumour AR C/N terminal ratio of ≥80% was associated with treatment benefit. At enzalutamide steady state, abiraterone acetate Cmin was ∼23% lower (range 14.05-200.5ng/ml) than when given alone. CONCLUSIONS: Enzalutamide combined with abiraterone acetate has a manageable safety profile, without a meaningful DDI. Both agents are pharmacodynamically active with no feedback. Efficacy findings do not support significant benefit of combined treatment for unselected bmCRPC. PATIENT SUMMARY: This is the first study combining enzalutamide plus abiraterone in bone metastatic castration-resistant prostate cancer. Results show that this combination is safe.
引用
- Efstathiou E, Titus M, Wen S, et al. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2019. PMID: 31412017. doi:10.1016/j.euo.2019.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。